Thromboxane b2

Thromboxane b2 is a lipid of Fatty Acyls (FA) class. Thromboxane b2 is associated with abnormalities such as endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia and Thrombocytosis. The involved functions are known as Platelet Activation, Excretory function, Anabolism, Inflammation and mRNA Expression. Thromboxane b2 often locates in Endothelium, Hepatic and Microsomes, Liver. The associated genes with Thromboxane b2 are PTGS2 gene, prothrombin fragment 2 and CCL14 wt Allele.

Cross Reference

Introduction

To understand associated biological information of Thromboxane b2, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Thromboxane b2?

Thromboxane b2 is suspected in endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia, Thrombocytosis, Acute Coronary Syndrome and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Thromboxane b2

MeSH term MeSH ID Detail
Arthritis, Experimental D001169 24 associated lipids
Arthritis D001168 41 associated lipids
Arteriosclerosis Obliterans D001162 8 associated lipids
Arteriosclerosis D001161 86 associated lipids
Arterial Occlusive Diseases D001157 12 associated lipids
Arrhythmias, Cardiac D001145 42 associated lipids
Aortic Rupture D001019 3 associated lipids
Aortic Arch Syndromes D001015 2 associated lipids
Aortic Aneurysm D001014 8 associated lipids
Hypoxia D000860 23 associated lipids
Per page 10 20 50 100 | Total 293

PubChem Associated disorders and diseases

What pathways are associated with Thromboxane b2

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Thromboxane b2?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Thromboxane b2?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

What genes are associated with Thromboxane b2?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with Thromboxane b2

Download all related citations
Per page 10 20 50 100 | Total 6367
Authors Title Published Journal PubMed Link
Fuchs I et al. Platelet hyperfunction is decreased by additional aspirin loading in patients presenting with myocardial infarction on daily aspirin therapy. 2010 Crit. Care Med. pmid:20400900
Steib CJ et al. Intraperitoneal LPS amplifies portal hypertension in rat liver fibrosis. 2010 Lab. Invest. pmid:20212458
Dragani A et al. The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy. 2010 Blood pmid:19887674
Kienzler JL et al. Systemic bioavailability of topical diclofenac sodium gel 1% versus oral diclofenac sodium in healthy volunteers. 2010 J Clin Pharmacol pmid:19841157
Butler BD et al. Circadian study of decompression sickness symptoms and response-associated variables in rats. 2010 Chronobiol. Int. pmid:20205563
Boizel R et al. Regulation of oxidative stress and inflammation by glycaemic control: evidence for reversible activation of the 5-lipoxygenase pathway in type 1, but not in type 2 diabetes. 2010 Diabetologia pmid:20535444
Liu H et al. Aspirin inhibits fractalkine expression in atherosclerotic plaques and reduces atherosclerosis in ApoE gene knockout mice. 2010 Cardiovasc Drugs Ther pmid:19997773
Cavalca V et al. Simultaneous quantification of 8-iso-prostaglandin-F(2alpha) and 11-dehydro thromboxane B(2) in human urine by liquid chromatography-tandem mass spectrometry. 2010 Anal. Biochem. pmid:19825360
Dharmasaroja PA and Sae-Lim S Effects of different doses, enteric-coated preparation of aspirin, and sex on urinary 11-dehydrothromboxane B2 in healthy volunteers. 2010 Blood Coagul. Fibrinolysis pmid:20689403
Milara J et al. Cigarette smoke exposure up-regulates endothelin receptor B in human pulmonary artery endothelial cells: molecular and functional consequences. 2010 Br. J. Pharmacol. pmid:20698855
Anauate MC et al. Effect of isolated fractions of Harpagophytum procumbens D.C. (devil's claw) on COX-1, COX-2 activity and nitric oxide production on whole-blood assay. 2010 Phytother Res pmid:20812280
Yassine HN et al. Clinical determinants of aspirin resistance in diabetes. 2010 Diabetes Res. Clin. Pract. pmid:20719400
Sato R et al. Inhibition of secretory phospholipase A2 activity attenuates lipopolysaccharide-induced acute lung injury in a mouse model. 2010 Exp. Lung Res. pmid:20426527
Wang BZ et al. [Association of the Pro1770Leu polymorphism in CYP5A1 gene with myocardial infarction in Uigur population of Xinjiang]. 2010 Zhonghua Yi Xue Yi Chuan Xue Za Zhi pmid:20931532
Dołegowska B et al. Dynamics of thromboxane level changes during early phase of allograft reperfusion. 2009 Sep-Oct Clin Transplant pmid:19298388
Tantry US et al. Aspirin resistance. 2009 Sep-Oct Prog Cardiovasc Dis pmid:19732606
Thomson VS et al. Aspirin resistance in Indian patients with coronary artery disease and cardiovascular events. 2009 Oct-Dec J Postgrad Med pmid:20083870
Goodman L et al. Effects of firocoxib and tepoxalin on healing in a canine gastric mucosal injury model. 2009 Jan-Feb J. Vet. Intern. Med. pmid:19175721
Zuo Y et al. Gross-total hematoma removal of hypertensive basal ganglia hemorrhages: a long-term follow-up. 2009 J. Neurol. Sci. pmid:19801153
Frelinger AL et al. Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization. 2009 Circulation pmid:19996015
Kambara T et al. Propofol suppresses prostaglandin E(2) production in human peripheral monocytes. 2009 Immunopharmacol Immunotoxicol pmid:19951072
Hu Y et al. Chinese herbal medicinal ingredients inhibit secretion of IL-6, IL-8, E-selectin and TXB2 in LPS-induced rat intestinal microvascular endothelial cells. 2009 Immunopharmacol Immunotoxicol pmid:19874221
Dietrich-Muszalska A and Olas B Isoprostenes as indicators of oxidative stress in schizophrenia. 2009 World J. Biol. Psychiatry pmid:19673085
Stanke-Labesque F et al. Increased urinary leukotriene E4 excretion in obstructive sleep apnea: effects of obesity and hypoxia. 2009 J. Allergy Clin. Immunol. pmid:19596146
Coates AM et al. Regular consumption of n-3 fatty acid-enriched pork modifies cardiovascular risk factors. 2009 Br. J. Nutr. pmid:18590592
Muir AR et al. Assessment of aspirin resistance varies on a temporal basis in patients with ischaemic heart disease. 2009 Heart pmid:18697805
Xu Y et al. Urocortin promotes the development of vasculitis in a rat model of thromboangiitis obliterans via corticotrophin-releasing factor type 1 receptors. 2009 Br. J. Pharmacol. pmid:19572944
Foudi N et al. Selective cyclooxygenase-2 inhibition directly increases human vascular reactivity to norepinephrine during acute inflammation. 2009 Cardiovasc. Res. pmid:18952694
Rogers LK et al. Differential responses in the lungs of newborn mouse pups exposed to 85% or >95% oxygen. 2009 Pediatr. Res. pmid:18703992
Fernández-Arche A et al. Long-chain fatty alcohols from pomace olive oil modulate the release of proinflammatory mediators. 2009 J. Nutr. Biochem. pmid:18555679
Shah KB et al. The cardioprotective effects of fish oil during pressure overload are blocked by high fat intake: role of cardiac phospholipid remodeling. 2009 Hypertension pmid:19597033
Zeng HH et al. [Effect of safflower injection on pulmonary hypertension in rat during chronic hypoxia and hypercapnia]. 2009 Zhongguo Ying Yong Sheng Li Xue Za Zhi pmid:21186611
Santilli F et al. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance". 2009 J. Am. Coll. Cardiol. pmid:19232899
Lev EI Aspirin resistance transient laboratory finding or important clinical entity? 2009 J. Am. Coll. Cardiol. pmid:19232900
Bernoud-Hubac N et al. Low concentrations of reactive gamma-ketoaldehydes prime thromboxane-dependent human platelet aggregation via p38-MAPK activation. 2009 Biochim. Biophys. Acta pmid:19233311
Giraudel JM et al. Differential inhibition of cyclooxygenase isoenzymes in the cat by the NSAID robenacoxib. 2009 J. Vet. Pharmacol. Ther. pmid:19161453
Jespersen B et al. Differential effects of immunosuppressive drugs on COX-2 activity in vitro and in kidney transplant patients in vivo. 2009 Nephrol. Dial. Transplant. pmid:19193738
Chen SS et al. Elevated plasma prostaglandins and acetylated histone in monocytes in Type 1 diabetes patients. 2009 Diabet. Med. pmid:19236624
Kanazawa S et al. Effect of low-dose aspirin for skin rash associated with erlotinib therapy in patients with lung cancer. 2009 Platelets pmid:19172526
Calapai G et al. Cardiovascular biomarkers in groups of established smokers after a decade of smoking. 2009 Basic Clin. Pharmacol. Toxicol. pmid:19175368
Kerola M et al. Effects of nimesulide, acetylsalicylic acid, ibuprofen and nabumetone on cyclooxygenase-1- and cyclooxygenase-2-mediated prostanoid production in healthy volunteers ex vivo. 2009 Basic Clin. Pharmacol. Toxicol. pmid:19152549
O'Donnell ME et al. The effects of cilostazol on exercise-induced ischaemia-reperfusion injury in patients with peripheral arterial disease. 2009 Eur J Vasc Endovasc Surg pmid:19112032
Bailey SR et al. Plasma concentrations of endotoxin and platelet activation in the developmental stage of oligofructose-induced laminitis. 2009 Vet. Immunol. Immunopathol. pmid:19091426
Dołegowska B et al. Platelets arachidonic acid metabolism in patients with essential hypertension. 2009 Platelets pmid:19440924
Ahmad M et al. Prolonged opportunity for neuroprotection in experimental stroke with selective blockade of cyclooxygenase-2 activity. 2009 Brain Res. pmid:19446533
Schuijt MP et al. The interaction of ibuprofen and diclofenac with aspirin in healthy volunteers. 2009 Br. J. Pharmacol. pmid:19466986
Eriksson AC et al. Static platelet adhesion, flow cytometry and serum TXB2 levels for monitoring platelet inhibiting treatment with ASA and clopidogrel in coronary artery disease: a randomised cross-over study. 2009 J Transl Med pmid:19508722
Cattaneo M Letter by cattaneo regarding article, "incomplete inhibition of thromboxane biosynthesis by acetylsalicylic Acid: determinants and effect on cardiovascular risk". 2009 Circulation pmid:19546394
Schiff M et al. Platelet inhibitory effects of OTC doses of naproxen sodium compared with prescription dose naproxen sodium and low-dose aspirin. 2009 Curr Med Res Opin pmid:19678751
Li L et al. The anti-inflammatory effects of ZLJ-6, a novel dual cyclooxygenase/5-lipoxygenase inhibitor. 2009 Eur. J. Pharmacol. pmid:19243697